Found 346 clinical trials
MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS
ULCERATIVE COLITIS IS AN INFLAMMATORY BOWEL DISEASE THAT CAUSES LONG-LASTING INFLAMMATION AND ULCERS (SORES) IN YOUR DIGESTIVE TRACT.
- 99 views
- 23 Nov, 2020
- 1 location
A Phase 2a, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients with Diarrhea predominant Irritable Bowel Syndrome (IBS-D)
no history of inflammatory or immune-mediated GI disorders including, but not limited to, inflammatory bowel disease (Crohn’s disease, ulcerative colitis, microscopic colitis, and celiac disease
- 292 views
- 20 Aug, 2019
- 1 location
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
- 171 views
- 08 Dec, 2020
- 1 location
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
- 229 views
- 25 Mar, 2021
- 1 location
Medical research study for people with Moderately to Severely Active Ulcerative Colitis
Medical research study for people with Moderately to Severely Active Ulcerative Colitis
- 109 views
- 08 Nov, 2020
- 1 location
COVID-19 VACCINE SAFETY AND EFFECTIVENESS
A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the …
- 0 views
- 02 Dec, 2021
- 1 location
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who …
- 4 views
- 05 Apr, 2023
- 141 locations
Boom-IBD Clinical Trial
Early feasibility study of neuromodulation in patients with IBD.
- 0 views
- 10 Apr, 2023
- 5 locations
Defining Predictors of RT Response to Vedolizumab in IBD
The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify response to vedolizumab in small bowel CD using objective endpoints. Current data suggest that MR …
- 12 views
- 07 Oct, 2022
- 1 location